conatumumab (AMG 655) / Amgen 
Welcome,         Profile    Billing    Logout  
 62 Diseases   0 Trials   0 Trials   48 News 
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Journal:  The generation of stable microvessels in ischemia is mediated by endothelial cell derived TRAIL. (Pubmed Central) -  Oct 4, 2024   
    Single-cell RNA sequencing revealed heparin-binding EGF-like growth factor in mediating EC-pericyte communications dependent on TRAIL. These studies highlight unique TRAIL-dependent mechanisms mediating neo-angiogenesis and vessel stabilization and the potential of repurposing TRAIL-R2 agonists to stimulate stable and functional microvessel networks to treat ischemia in PAD.
  • ||||||||||  ganitumab (AMG 479) / Takeda, ImmunityBio
    Phase classification, Combination therapy, Metastases:  QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors (clinicaltrials.gov) -  Aug 20, 2024   
    P1/2,  N=89, Terminated, 
    These studies highlight unique TRAIL-dependent mechanisms mediating neo-angiogenesis and vessel stabilization and the potential of repurposing TRAIL-R2 agonists to stimulate stable and functional microvessel networks to treat ischemia in PAD. Phase classification: P1b/2 --> P1/2
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Journal:  TRAIL-Based Therapies Efficacy in Pediatric Bone Tumors Models Is Modulated by TRAIL Non-Apoptotic Pathway Activation via RIPK1 Recruitment. (Pubmed Central) -  Nov 27, 2022   
    The DR5 agonist antibody AMG655 (Conatumumab) was selected as an example of TRAIL-based therapy...We proposed two independent strategies to overcome this issue: (1) a proof-of-concept targeting of RIPK1 by shRNA approach and (2) the use of a novel highly-potent TRAIL-receptor agonist; both shifting the balance in favor of apoptosis. These observations are paving the way to resurrect TRAIL-based therapies in pediatric bone tumors to help predict the response to treatment, and propose a relevant adjuvant strategy for future therapeutic development.
  • ||||||||||  irinotecan / Generic mfg.
    Preclinical, Journal:  DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. (Pubmed Central) -  Jun 22, 2021   
    To take advantage of elevated expression of this pathway, we designed drug-loaded NPs with a surface-conjugated αDR5 antibody (AMG 655)...Moreover, the DNA topoisomerase-1 inhibitor camptothecin (CPT) down-regulated FLIP in pancreatic cancer models and enhanced apoptosis induced by αDR5-NPs...Importantly, CPT-loaded αDR5-NPs markedly reduced tumor growth rates in vivo in established pancreatic tumor models, inducing regressions in one model. These proof-of-concept studies indicate that αDR5-NPs loaded with agents that downregulate or inhibit FLIP are promising candidate agents for the treatment of pancreatic cancer.
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Journal:  The serum protein transthyretin as a platform for dimerization and tetramerization of antibodies and Fab fragments to enable target clustering. (Pubmed Central) -  Jan 14, 2021   
    These proof-of-concept studies indicate that αDR5-NPs loaded with agents that downregulate or inhibit FLIP are promising candidate agents for the treatment of pancreatic cancer. Transthyretin (TTR) is an abundant homo-tetrameric serum protein and was selected here for engineering higher-valency molecules because its compact size, simple structure, and natural propensity to tetramerize.   To demonstrate this utility, we fused TTR to the C terminus of conatumumab, an antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), as heavy chains to form antibody dimers and Fab heavy chains to form Fab tetramers.  Moreover, we used constant heavy domain 3 (CH3) heterodimerization substitutions to create TTR-mediated conatumumab tetramers.  The conatumumab-TTR fusions displayed substantially enhanced potency in cell-based assays as well as in murine tumor xenograft models.  We conclude that antibody-TTR fusions may provide a powerful platform for multimerizing antibody and Fab fragments to enhance the capabilities of human therapeutics that benefit from target clustering and higher-order antigen-binding valency.
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial completion date, Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Dec 19, 2019   
    P2,  N=12, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: Nov 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Mar 2020
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial completion date, Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Nov 6, 2018   
    P2,  N=12, Active, not recruiting, 
    Trial completion date: Nov 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Mar 2020 Trial completion date: Jan 2019 --> Nov 2019 | Trial primary completion date: Jan 2019 --> Sep 2019
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial completion date, Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Jul 18, 2018   
    P2,  N=12, Active, not recruiting, 
    Trial completion date: Jan 2019 --> Nov 2019 | Trial primary completion date: Jan 2019 --> Sep 2019 Trial completion date: Jul 2018 --> Jan 2019 | Trial primary completion date: Jul 2018 --> Jan 2019
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Nov 30, 2017   
    P2,  N=12, Active, not recruiting, 
    Further research is needed to achieve effective therapy for patients with EGFR mutation L858R or nonsquamous histology. Trial primary completion date: Jan 2018 --> Jul 2018
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Jul 31, 2017   
    P2,  N=12, Active, not recruiting, 
    Trial primary completion date: Jan 2018 --> Jul 2018 Trial primary completion date: Jul 2017 --> Jan 2018
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Feb 15, 2017   
    P2,  N=12, Active, not recruiting, 
    Trial primary completion date: Jul 2017 --> Jan 2018 Trial primary completion date: Jan 2017 --> Jul 2017
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  May 9, 2016   
    P2,  N=12, Active, not recruiting, 
    Phase classification: P1/2 --> P1b/2 Trial primary completion date: Jul 2016 --> Jan 2017
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Nov 27, 2015   
    P2,  N=12, Active, not recruiting, 
    Active, not recruiting --> Completed | N=40 --> 27 Trial primary completion date: Dec 2015 --> Jul 2016
  • ||||||||||  birinapant (IGM-9427) / IGM Biosciences, conatumumab (AMG 655) / Amgen
    Enrollment closed, Trial primary completion date:  Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer (clinicaltrials.gov) -  Jun 1, 2015   
    P1,  N=40, Active, not recruiting, 
    Trial primary completion date: Dec 2015 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Aug 2015
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Apr 20, 2015   
    P2,  N=12, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Aug 2015 Trial primary completion date: Apr 2015 --> Dec 2015
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Enrollment closed, Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Feb 20, 2015   
    P2,  N=12, Active, not recruiting, 
    Trial primary completion date: Apr 2015 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015
  • ||||||||||  birinapant (IGM-9427) / IGM Biosciences, conatumumab (AMG 655) / Amgen
    Trial primary completion date:  Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer (clinicaltrials.gov) -  Oct 15, 2014   
    P1,  N=40, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015 Trial primary completion date: Sep 2014 --> Apr 2015